| Name | Title | Contact Details |
|---|
Born from the founders` recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
The mission at Ascus Biosciences is better microbes for a better life. Based in San Diego, CA, Ascus is focused on discovering, developing, and commercializing first-in-class endomicrobial products for the animal health and nutrition industries.
NOCION is a biopharmaceutical company that is addressing vexing medical problems head on. We are developing `nocions`—a new kind of therapy that selectively affects actively firing nocioceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.